Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.

Trial Details

NCT ID
NCT05270200
Phase
PHASE1 / PHASE2
Sponsor
Zhujiang Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Chidamide
Locations (sample)
  • Guanzhou, Guandong, China|28.41559,109.01843

Key Eligibility Criteria

  • Age 18 to 60 years old,both male and female
  • Be able to understand and sign informed consent
  • Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic
  • Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →